Evidence map›Paper›PMID 38110712›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2024

Treatment response assessment in transthyretin-related cardiac amyloidosis: an emerging clinical indication of bone-seeking radiopharmaceuticals?

Olivier Gheysens, Giorgio Treglia, Ahmad Masri, Fabien Hyafil, Sharmila Dorbala

Open access · bronzeAbstract readEditorial
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. 2025 Update Consensus ofActa Cardiologica Sinica · 2025
    Article
  2. Collection on molecular imaging in cardiac amyloidosis.European journal of nuclear medicine and molecular imaging · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 5 institutions in 4 countries.

Olivier GheysensDepartment of Nuclear Medicine, Cliniques Universitaires Saint-Luc and Institute for Experimental and Clinical Research (IREC), Université Catholique de Louvain, Avenue Hippocrate 10, 1200, Brussels, Belgium. Olivier.gheysens@uclouvain.be.
Giorgio TregliaDivision of Nuclear Medicine, Imaging Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
Ahmad MasriAmyloidosis Center, Knight Cardiovascular Institute, Oregon Health and Science University, Portland, OR, USA.
Fabien HyafilDepartment of Nuclear Medicine, AP-HP, European Hospital Georges Pompidou, University of Paris-Cité, Paris, France.
Sharmila DorbalaDivision of Nuclear Medicine and Molecular Imaging, Department of Radiology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Assistance Publique – Hôpitaux de Paris · FRBrigham and Women's Hospital · USCliniques Universitaires Saint-Luc · BEOregon Health & Science University · USUniversità della Svizzera italiana · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Amyloid Neuropathies, FamilialCardiomyopathiesBone and BonesHumansPrealbuminRadiopharmaceuticalsPrealbuminRadiopharmaceuticals

Identifiers

PMID38110712
OpenAlexW4389903081

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.